HPHA Stock Overview
Heidelberg Pharma AG, a biopharmaceutical company, focuses on oncology and antibody targeted amanitin conjugates (ATAC) in Germany, other European countries, the United States, and internationally.
Capture your thoughts, links and company narrative
Heidelberg Pharma AG Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||€3.83|
|52 Week High||€6.50|
|52 Week Low||€3.70|
|1 Month Change||-4.25%|
|3 Month Change||-19.87%|
|1 Year Change||-24.90%|
|3 Year Change||-10.09%|
|5 Year Change||43.99%|
|Change since IPO||-92.76%|
Recent News & Updates
Analyst Forecasts For Heidelberg Pharma AG (ETR:HPHA) Are Surging HigherOct 16
Heidelberg Pharma (ETR:HPHA) Will Have To Spend Its Cash WiselyNov 28
Heidelberg Pharma AG (ETR:HPHA) Analysts Are More Bearish Than They Used To BeMar 27
We Think Heidelberg Pharma (ETR:HPHA) Needs To Drive Business Growth CarefullyMar 15
Investors Who Bought Heidelberg Pharma (ETR:HPHA) Shares Five Years Ago Are Now Up 245%Jan 17
We Think Heidelberg Pharma (ETR:HPHA) Needs To Drive Business Growth CarefullyDec 14
|HPHA||DE Biotechs||DE Market|
Return vs Industry: HPHA underperformed the German Biotechs industry which returned -8% over the past year.
Return vs Market: HPHA underperformed the German Market which returned -7.6% over the past year.
|HPHA Average Weekly Movement||3.5%|
|Biotechs Industry Average Movement||6.4%|
|Market Average Movement||5.0%|
|10% most volatile stocks in DE Market||10.0%|
|10% least volatile stocks in DE Market||2.7%|
Stable Share Price: HPHA is less volatile than 75% of German stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: HPHA's weekly volatility (4%) has been stable over the past year.
About the Company
Heidelberg Pharma AG, a biopharmaceutical company, focuses on oncology and antibody targeted amanitin conjugates (ATAC) in Germany, other European countries, the United States, and internationally. Its lead product candidate is HDP-101, which in the Phase I/IIa study for the treatment of relapsed or refractory multiple myeloma. The company is developing HDP-102 for the treatment of non-Hodgkin lymphoma; HDP-103, an ATAC candidate to treat metastatic castration-resistant prostate cancer; HDP-104 for the treatment of gastrointestinal tumors; HDP-XX for the treatment of solid/hematological tumors; MGTA-ATACs for HSCs, conditioning programs to treat blood cancers/genetic diseases; and TAK-ATACs for oncology.
Heidelberg Pharma AG Fundamentals Summary
|HPHA fundamental statistics|
Is HPHA overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|HPHA income statement (TTM)|
|Cost of Revenue||€5.50m|
Last Reported Earnings
Feb 28, 2023
Next Earnings Date
Jul 13, 2023
|Earnings per share (EPS)||-0.41|
|Net Profit Margin||-95.11%|
How did HPHA perform over the long term?See historical performance and comparison